Jazz' $700 million EUSA buy diversifies portfolio and broadens reach
This article was originally published in Scrip
Jazz Pharmaceuticals PLC will increase its international presence and diversify its specialty pharma portfolio with the $700 million purchase of EUSA Pharma.
You may also be interested in...
Stockwatch: Is Biotech Investing A State Of Mind?
The American Society for Clinical Oncology (ASCO) conference that has just opened in Chicago is traditionally thought of as one of the key catalysts of the year for biotechnology and pharmaceutical companies. The stock prices of companies presenting their latest data usually run up in anticipation of ASCO and subsequently sell off after the conference. While this is now expected by investors, this year may be different.
Ionis Invests For The Future In New Technologies, Manufacturing Innovation
Through partnerships with Bicycle and Metagenomi, Ionis is working on new chemistries and novel medicines. It is also expanding manufacturing capacity to enable its scientific growth.
Ionis Finds Its Footing Ahead Of Its First Big Commercial Step
Ionis will launch its first commercial product through a co-commercialization agreement with AstraZeneca early next year, in preparation for its first wholly-owned drug launches soon to follow.